Abivax S.a. (ABVX)

$12.35

+0.07

(+0.57%)

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $11.89
    $12.35
    $12.35
    downward going graph

    3.72%

    Downside

    Day's Volatility :3.73%

    Upside

    0.01%

    downward going graph
  • $8.00
    $17.02
    $12.35
    downward going graph

    35.26%

    Downside

    52 Weeks Volatility :53.03%

    Upside

    27.44%

    downward going graph

Returns

PeriodAbivax S.a.Index (Russel 2000)
3 Months
-13.61%
0.0%
6 Months
-14.83%
0.0%
1 Year
48.8%
0.0%
3 Years
48.8%
-22.3%

Highlights

Market Capitalization
772.6M
Book Value
$3.12
Earnings Per Share (EPS)
-3.79
Wall Street Target Price
36.14
Profit Margin
0.0%
Operating Margin TTM
-4016.79%
Return On Assets TTM
-39.57%
Return On Equity TTM
-145.41%
Revenue TTM
4.5M
Revenue Per Share TTM
0.1
Quarterly Revenue Growth YOY
-0.1%
Gross Profit TTM
0.0
EBITDA
-127.3M
Diluted Eps TTM
-3.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-3.19
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Abivax S.a.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 192.63%

Current $12.35
Target $36.14

Technicals Summary

Sell

Neutral

Buy

Abivax S.a. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abivax S.a.
Abivax S.a.
9.68%
-14.83%
48.8%
48.8%
48.8%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abivax S.a.
Abivax S.a.
NA
NA
NA
0.0
-1.45
-0.4
NA
3.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abivax S.a.
Abivax S.a.
Buy
$772.6M
48.8%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Company Information

Organization
Abivax S.a.
Employees
61
CEO
Mr. Marc M. P. de Garidel M.B.A.
Industry
Miscellaneous

FAQs